Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ARESTOCAINE HYDROCHLORIDE vs CHOLAC
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Arestocaine hydrochloride is a local anesthetic of the amide type. It stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthesia.
Lactulose is a synthetic disaccharide that is not absorbed in the small intestine. It is metabolized by colonic bacteria to short-chain fatty acids, primarily lactic acid and acetic acid, which lower the colonic p H. This acidification traps ammonia (NH3) as ammonium (NH4+) in the gut lumen, reducing serum ammonia levels. Additionally, the osmotic effect of lactulose draws water into the colon, producing a laxative effect.
Local or regional anesthesia for dental procedures,Infiltration anesthesia,Nerve block anesthesia
Treatment of hepatic encephalopathy (portal-systemic encephalopathy) in patients with acute and chronic liver disease,Constipation (including chronic idiopathic constipation)
2-5 mg/kg intramuscularly every 60-90 minutes, not to exceed 500 mg total dose in a 12-hour period.
15-30 m L (10-20 g lactulose) orally once daily, titrated to produce 2-3 soft stools per day; maximum dose 60 m L/day. For hepatic encephalopathy: 30-45 m L (20-30 g) orally 3-4 times daily, titrated to 2-3 soft stools per day.
Terminal elimination half-life is approximately 1.5–2 hours in adults with normal hepatic and renal function; prolonged in hepatic impairment or congestive heart failure.
0.5-1.5 hours for lactulose; active metabolites (e.g., acetic acid) have negligible systemic half-life due to rapid local metabolism.
Primarily metabolized by the liver via hydrolysis by esterases (though it is an amide, it may be partially hydrolyzed) and conjugation. The major metabolic pathways involve CYP1A2 and CYP3A4.
Not absorbed systemically. Metabolized by colonic bacteria (e.g., Lactobacillus, Bacteroides) to lactic acid, acetic acid, and other short-chain fatty acids.
Renal excretion of unchanged drug and metabolites; approximately 90% excreted in urine as parent compound and metabolites (60% as unchanged drug, 30% as metabolites), with less than 10% fecal elimination.
Primarily fecal (biliary excretion of unchanged drug and metabolites); minimal renal excretion (<5%).
Approximately 70% bound primarily to alpha-1-acid glycoprotein (AAG) and to a lesser extent albumin.
Negligible (<1%); not significantly bound to plasma proteins.
Volume of distribution is 0.8–1.5 L/kg, reflecting extensive tissue distribution; higher in neonates and infants.
Approximately 0.2 L/kg; indicates distribution primarily in extracellular fluid.
Topical: variable, approximately 30–50% absorbed through intact skin; Oral: negligible due to extensive first-pass metabolism (bioavailability <10%); Intravenous: 100%.
Oral: <2% systemic bioavailability due to extensive first-pass metabolism and local gut action; rectal: minimal systemic absorption.
GFR 30-50 m L/min: reduce dose by 25%; GFR 15-29 m L/min: reduce dose by 50%; GFR <15 m L/min: avoid use.
No dose adjustment required for renal impairment.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
No specific Child-Pugh based adjustments. Use with caution in severe hepatic impairment due to risk of electrolyte disturbances; monitor serum electrolytes.
1-3 mg/kg intramuscularly every 60-90 minutes, max 200 mg per dose; maximum cumulative dose 400 mg/12 hours.
Infants: 2.5-10 m L/day in divided doses. Children: 40-90 mg/kg/day (as lactulose) divided 1-2 times daily, titrated to produce soft stools. For hepatic encephalopathy: 2.5-10 m L (1.7-6.7 g) orally 3-4 times daily, titrated to 2-3 soft stools per day.
Initiate at lowest effective dose (2 mg/kg) due to increased sensitivity and potential for prolonged duration; monitor for adverse effects.
Initiate at lower end of dosing range (15 m L once daily) and titrate slowly to avoid diarrhea and electrolyte imbalance; monitor renal function and electrolytes.
There is no FDA black box warning for Arestocaine hydrochloride.
No FDA black box warning.
Risk of systemic toxicity if injected intravascularly,Use with caution in patients with hepatic impairment,Use with caution in patients with cardiovascular disease,Risk of methemoglobinemia in patients with glucose-6-phosphate dehydrogenase deficiency
Electrolyte disturbances (e.g., hypernatremia) may occur, especially with prolonged use or in patients with renal impairment,Diarrhea can lead to fluid and electrolyte loss; dosage should be adjusted to produce 2-3 soft stools per day,Galactose content: lactulose contains galactose and lactose; use with caution in patients with galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption,Risk of colonic perforation in patients with severe colonic ulceration, toxic megacolon, or gastrointestinal obstruction
Hypersensitivity to amide-type local anesthetics,Severe hypotension,Myasthenia gravis (relative contraindication),Bradycardia
Patients with galactosemia (due to galactose content),Gastrointestinal obstruction (including ileus),Hypersensitivity to lactulose or any component of the formulation
No specific food interactions; avoid hot foods until numbness resolves to prevent burns.
No specific food restrictions. Mixing with fruit juice, water, or milk may improve taste. Avoid excessive intake of dairy products if lactose intolerant (lactulose may contain small amounts of lactose).
Pregnancy Category C. Animal reproduction studies have not been conducted. In first trimester, limited data; potential for adverse effects on fetal development cannot be excluded. In second and third trimesters, risk of placental transfer and fetal bradycardia; use only if clearly needed.
Lactulose is not absorbed systemically; no teratogenic effects reported in animal studies or human case reports. FDA Pregnancy Category B. Trimester-specific risks: no known fetal harm in any trimester.
No data on excretion in human milk. M/P ratio unknown. Caution advised; discontinue breastfeeding or drug based on importance of drug to mother.
Excretion into breast milk is negligible due to minimal systemic absorption. M/P ratio not determined. Considered compatible with breastfeeding.
Increased plasma volume and decreased plasma protein binding may require dose adjustments. However, no established guidelines; use lowest effective dose and shortest duration.
No dose adjustment required during pregnancy; pharmacokinetics unchanged due to localized GI action.
ARESTOCAINE HYDROCHLORIDE (presumed anesthetic) is not a recognized drug; likely a misspelling of articaine or similar. If referring to articaine, clinical pearls: 1) Onset within 1-3 minutes, duration 1-3 hours; 2) Metabolized by plasma esterases, caution in pseudocholinesterase deficiency; 3) Maximum dose 7 mg/kg (adults) to avoid CNS/cardiac toxicity; 4) Contains sulfites, avoid in allergic patients.
Cholac (lactulose) is used for constipation and hepatic encephalopathy. Monitor for diarrhea and electrolyte imbalances. In hepatic encephalopathy, titrate dose to achieve 2-3 soft stools per day. Syrup can be mixed with fruit juice or water to improve palatability. Onset of action is 24-48 hours for constipation; for encephalopathy, effects may take several days.
Avoid chewing or biting lips/cheeks while numb to prevent injury.,Report any signs of allergic reaction (rash, swelling, difficulty breathing) immediately.,Do not consume hot foods or beverages until sensation returns.,Inform dentist of all medications, especially MAOIs or anticoagulants.
Take exactly as prescribed. Do not change dose without consulting your doctor.,For constipation, effects may take up to 48 hours. Do not use other laxatives unless advised.,For liver disease, it helps reduce ammonia levels. Aim for 2-3 soft bowel movements daily.,May cause gas, bloating, or stomach cramps, which usually decrease over time.,Contact doctor if you have severe diarrhea, vomiting, or signs of dehydration.,Store at room temperature, away from heat and direct light.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ARESTOCAINE HYDROCHLORIDE vs CHOLAC, answered by our medical review team.
ARESTOCAINE HYDROCHLORIDE is a Local Anesthetic that works by Arestocaine hydrochloride is a local anesthetic of the amide type. It stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthesia.. CHOLAC is a Laxative that works by Lactulose is a synthetic disaccharide that is not absorbed in the small intestine. It is metabolized by colonic bacteria to short-chain fatty acids, primarily lactic acid and acetic acid, which lower the colonic p H. This acidification traps ammonia (NH3) as ammonium (NH4+) in the gut lumen, reducing serum ammonia levels. Additionally, the osmotic effect of lactulose draws water into the colon, producing a laxative effect.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ARESTOCAINE HYDROCHLORIDE and CHOLAC depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ARESTOCAINE HYDROCHLORIDE is: 2-5 mg/kg intramuscularly every 60-90 minutes, not to exceed 500 mg total dose in a 12-hour period.. The standard adult dose of CHOLAC is: 15-30 m L (10-20 g lactulose) orally once daily, titrated to produce 2-3 soft stools per day; maximum dose 60 m L/day. For hepatic encephalopathy: 30-45 m L (20-30 g) orally 3-4 times daily, titrated to 2-3 soft stools per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ARESTOCAINE HYDROCHLORIDE and CHOLAC in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ARESTOCAINE HYDROCHLORIDE is classified as Category C. Pregnancy Category C. Animal reproduction studies have not been conducted. In first trimester, limited data; potential for adverse effects on fetal development cannot be excluded. . CHOLAC is classified as Category C. Lactulose is not absorbed systemically; no teratogenic effects reported in animal studies or human case reports. FDA Pregnancy Category B. Trimester-specific risks: no known fetal . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.